Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,385.00 DKK | +0.04% |
|
-1.77% | -7.20% |
01-31 | Genmab and Pfizer receive positive opinion on Tidvak | FW |
01-24 | Goldman Sachs lowers target price for Genmab to DKK 2,066 (2,425), reiterates neutral - BN | FW |
Fundamentals | Valuation | Consensus | Revisions of Fundamental Estimates | Visibility | Investor | ESG MSCI | Capi.($) | ||
---|---|---|---|---|---|---|---|---|---|
AA | 12.23B | ||||||||
AA | 124B | ||||||||
A | 77.28B | ||||||||
- | - | 28.75B | |||||||
AA | 22.89B | ||||||||
A | 15.24B | ||||||||
AAA | 11.13B | ||||||||
BBB | 10.71B | ||||||||
BB | 9.62B | ||||||||
B | 7.31B | ||||||||
A | 7.18B | ||||||||
Average | A | 29.66B | |||||||
Weighted average by Cap. | A |
- Stock Market
- Equities
- GMAB Stock
- Sector Genmab A/S
- Sector ratings

MarketScreener is also available in this country: United States.
Switch edition